Blog
RSS FeedPosted by Michael Wonder on 25 Aug 2022
Lynparza approved in Japan as adjuvant treatment for patients with BRCA mutated HER2 negative high-risk early breast cancer
25 August 2022 - First and only approved medicine targeting BRCA mutations in early breast cancer ...
Posted by Michael Wonder on 25 Aug 2022
AB Science announces that it has filed an application for conditional marketing authorisation to EMA for masitinib in the treatment of ALS
24 August 2022 - AB Science today announced that it has filed an application for conditional marketing authorisation to the EMA ...
Posted by Michael Wonder on 25 Aug 2022
Children with chronic graft versus host disease may now be prescribed Imbruvica (ibrutinib)
24 August 2022 - This is the first approved treatment option for children with cGVHD under 12 years of age and ...
Posted by Michael Wonder on 24 Aug 2022
Lifesaving cancer treatment out of reach for rural people
23 August 2022 - CAR T-cell therapy eradicates cancer in some patients but remains inaccessible to people who live far from ...
Posted by Michael Wonder on 24 Aug 2022
Prescription medicines: applications under evaluation
24 August 2022 - The TGA has updated its list of applications for new medicines or new uses for existing ...
Posted by Michael Wonder on 24 Aug 2022
Roche withdraws application for Tecentriq
25 August 2022 - Publication of AusPAR reveals the withdrawal of the application in July 2021. ...
Posted by Michael Wonder on 24 Aug 2022
FDA approves ibrutinib for paediatric patients with chronic graft versus host disease, including a new oral suspension
24 August 2022 - Today, the FDA approved ibrutinib (Imbruvica, Pharmacyclics) for paediatric patients ≥ 1 year of age with ...
Posted by Michael Wonder on 24 Aug 2022
Access criteria for new COVID-19 treatment announced
25 August 2022 - PHARMAC has today confirmed the access criteria for the first preventative medicine for COVID-19, tixagevimab and cilgavimab ...
Posted by Michael Wonder on 24 Aug 2022
How a long-overlooked protein could remake neuroscience drug discovery — or plunge the FDA into controversy
24 August 2022 - So, imagine you get punched in the head. Not once, but a bunch of times. ...
Posted by Michael Wonder on 24 Aug 2022
Avalglucosidase alfa for treating Pompe disease
24 August 2022 - NICE has published evidence-based recommendations on the use of avalglucosidase alfa for the treatment of patients ...
Posted by Michael Wonder on 23 Aug 2022
The EU HTA regulation: a new frontier for access to innovative technologies
23 August 2022 - A new health technology regulation is due to be applied to help EU countries determine the effectiveness ...
Posted by Michael Wonder on 23 Aug 2022
Health Canada approves Opdivo (nivolumab) with chemotherapy as neo-adjuvant treatment for adult patients with resectable non-small-cell lung cancer
23 August 2022 - First and only immunotherapy-based treatment for use before surgery for non-small-cell lung cancer in Canada. ...
Posted by Michael Wonder on 23 Aug 2022
Hiring and data: how the US will set up new Medicare drug price talks
23 August 2022 - The US Government will soon begin hiring experts and collecting the data needed to launch direct ...
Posted by Michael Wonder on 23 Aug 2022
AstraZeneca's Soriot warns new US drug price law will hurt innovation
23 August 2022 - AstraZeneca's Chief Executive Pascal Soriot warned on Tuesday new US legislation capping drug prices would reduce ...
Posted by Michael Wonder on 23 Aug 2022
European Medicines Agency commences review of oral fixed-dose combination of decitabine and cedazuridine for the treatment of adults with acute myeloid leukaemia
22 August 2022 - Otsuka and Astex Pharmaceuticals today announce that the EMA has accepted the marketing authorisation application for the ...